Mycophenolate Mofetil Biogaran (Mycophenolate Mofetil)

• Mycophenolate Mofetil is used within the transplant immunology pathway to reduce immune‑mediated graft injury.
• Kidney transplant: lowers the incidence of acute rejection and supports long‑term graft survival.
• Liver transplant: maintains hepatic graft function by suppressing T‑cell activation.
• Heart transplant: prevents immune‑driven damage to the cardiac allograft.

• Mycophenolate Mofetil is converted intracellularly to mycophenolic acid, which selectively inhibits inosine monophosphate dehydrogenase (IMPDH). This blockade reduces guanosine nucleotide synthesis, a critical step for DNA replication in activated T‑ and B‑lymphocytes, thereby suppressing their proliferation and dampening the immune response that leads to graft rejection.

Mycophenolate Mofetil may cause a range of adverse reactions.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: frequent loose stools, often self‑limiting.
• Vomiting: occasional episodes, especially after dose initiation.
• Abdominal pain: cramping or discomfort in the stomach area.
• Headache: transient, usually resolves without intervention.
• Infections: increased susceptibility to common bacterial or viral infections.

Serious or Rare Side Effects

• Leukopenia: significant reduction in white blood cells, raising infection risk.
• Anemia: decreased red blood cell count leading to fatigue.
• Severe infections: opportunistic infections such as CMV or fungal disease.
• Malignancy: heightened long‑term risk of certain cancers.
• Hepatic toxicity: elevated liver enzymes or hepatitis.
• Progressive multifocal leukoencephalopathy (PML): rare, potentially fatal brain infection.

• Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor laboratory parameters.
• Monitor blood counts: perform regular complete blood count to detect leukopenia or anemia.
• Assess renal function: check serum creatinine and glomerular filtration rate periodically.
• Avoid in known hypersensitivity: discontinue if allergic reactions occur.
• Use caution in pregnancy: safety category unknown; weigh benefits against potential fetal risks.
• Adjust dose in hepatic impairment: consider reduced dosing for patients with liver dysfunction.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mycophenolate Mofetil can interact with several concomitant medicines, requiring careful management.

Major Interactions (Avoid)

• Azathioprine: additive bone‑marrow suppression, increasing risk of cytopenias.
• Cyclosporine: raises mycophenolate exposure, potentially intensifying toxicity.
• Tacrolimus: similar effect as cyclosporine, may require dose adjustment.
• Live vaccines: heightened risk of vaccine‑derived infection.
• Rifampin: induces metabolism, markedly lowering mycophenolate levels.

Moderate Interactions (Monitor Closely)

• Antacids (e.g., aluminum‑magnesium): may reduce absorption of mycophenolic acid.
• Cholestyramine: binds drug in gut, decreasing systemic exposure.
• Valganciclovir: combined myelosuppression risk, monitor blood counts.
• NSAIDs: can affect renal function, especially in transplant recipients.
• ACE inhibitors: potential for hyperkalemia when renal function is compromised.